Your browser doesn't support javascript.
loading
Evaluation of the use of the Scale for the Assessment and Rating of Ataxia (SARA) in healthy volunteers and patients with schizophrenia.
Shaafi Kabiri, Nina; Syed, Sana; Bali, Taha; Karlin, Daniel R; Binneman, Brendon; Tan, Ye; Steinman, Alexii; Cote, Alanna C; Thomas, Kevin C.
Afiliação
  • Shaafi Kabiri N; Laboratory for Human Neurobiology, Department of Anatomy and Neurobiology, Boston University School of Medicine, 650 Albany Street, Unit X140, Boston, MA 02118, USA.
  • Syed S; Tufts Medical Center, Department of Neurology, USA; Pfizer Inc. Worldwide Research & Development, 610 Main Street, Cambridge, MA, USA.
  • Bali T; Massachusetts General Hospital, Department of Neurology, USA; Pfizer Inc. Worldwide Research & Development, 610 Main Street, Cambridge, MA, USA.
  • Karlin DR; Pfizer Inc. Worldwide Research & Development, 610 Main Street, Cambridge, MA, USA; Tufts University School of Medicine, Department of Psychiatry, Boston, MA, USA.
  • Binneman B; Pfizer Inc. Worldwide Research & Development, 610 Main Street, Cambridge, MA, USA.
  • Tan Y; Tufts University School of Medicine, Department of Psychiatry, Boston, MA, USA.
  • Steinman A; Pfizer Inc. Worldwide Research & Development, 610 Main Street, Cambridge, MA, USA.
  • Cote AC; Laboratory for Human Neurobiology, Department of Anatomy and Neurobiology, Boston University School of Medicine, 650 Albany Street, Unit X140, Boston, MA 02118, USA.
  • Thomas KC; Laboratory for Human Neurobiology, Department of Anatomy and Neurobiology, Boston University School of Medicine, 650 Albany Street, Unit X140, Boston, MA 02118, USA. Electronic address: kipthoma@bu.edu.
J Neurol Sci ; 391: 40-44, 2018 08 15.
Article em En | MEDLINE | ID: mdl-30103968
OBJECTIVE: The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment used to evaluate ataxia. The goal of these studies was to assess and evaluate the utility of this instrument in a Healthy Volunteer (HV) group and subjects with Schizophrenia (SCZ). METHODS: Two studies were completed to collect SARA data, in a HV group and in a stable SCZ group. 177 HVs (18-65 years) and 16 SCZs (18-58 years) provided written consent and were assessed using the SARA. Of 177 HV subjects, 88 had 2 SARA assessments (within 2 days of initial visit) while all 16 SCZ had 3 SARA assessments (within 14 days of initial visit). RESULTS: For the HV group, the mean score ±â€¯Std for the SARA on visit-1 was 0.39 ±â€¯0.72, and 0.34 ±â€¯0.64 for visit-2. The Pearson correlation coefficient between visit-1 and visit-2 was 0.7486 and an ICC of 0.743. For the SCZ group, the mean score for the SARA was 0.63 ±â€¯0.65 on visit-1, 0.84 ±â€¯1.19 on visit-2, and 0.84 ±â€¯0.94 on visit-3. The Pearson correlation coefficient between visit-1 and visit-2 was 0.6545, between visit-1 and visit-3 was 0.6635 and between visit-2 and visit-3 was 0.7613 and an ICC of 0.650. There was no significant difference in baseline SARA scores between the HV and SCZ group p = .063. A statistically significant positive association between age and total SARA scores was observed in HV (r = 0.345) and SCZ (r = 0.676). CONCLUSIONS: A strong association was observed in both the HV and SCZ groups in the reassessment of signs of ataxia using the SARA scale. Both groups demonstrated minimal signs of ataxia, with no statistically significant difference between the two groups in their visit-1 scores.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia / Esquizofrenia Tipo de estudo: Diagnostic_studies / Evaluation_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ataxia / Esquizofrenia Tipo de estudo: Diagnostic_studies / Evaluation_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article